2nd Annual TGF-β for Immuno-Oncology Drug Development

Tuesday, January 25th – Thursday, January 27th

Digital Event:
Click here for access

 Overview:

Outcome’s Dr. John Armstrong will be providing An Overview of the TGF-β IO Market including:

  • Current approaches in the TGF-β IO market
  • Recent M&A, equity financing, and strategic partnership transactions in the TGF- β IO market
  • How to position your company, team, and asset for a successful entry into the TGF-β IO market

For more information, please contact jarmstrong@outcomecapital.com

News

Outcome Capital Advises ELIOS Vision on Growth Financing Round

BOSTON–(BUSINESS WIRE)–Outcome Capital, a highly specialized life sciences and healthcare advisory and investment banking firm, today announced that ELIOS Vision, Inc. completed a growth financing round to support its European commercialization. Outcome Capital served as the exclusive strategic and financial advisor to the company. ELIOS’ implant-free, minimally invasive Excimer Laser Trabeculostomy glaucoma procedure is approved […]

Read More
Resources

Outcome Capital Life Sciences Pulse

Outcome Capital Life Science Market Pulse July 2022 Click to view our LifeSciences Pulse Newsletter

Download

Contact Us for More Information

Would you like to learn more about working with Outcome Capital or discuss your specific needs?

Contact Us

  • Boston

    99 High St. Suite 2900, Boston, MA 02110
    (617) 431-2278

© Outcome Capital 2022. Member of Financial Industry Regulatory Authority (FINRA) and the Securities Investment Protection Corporation (SIPC). Check the background of this firm on FINRA’s BrokerCheck.

Business Continuity Plan | Privacy Policy

Built by Metropolis